Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2010 - A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study).

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Jean-Marc Nabholtz

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

J. Nabholtz1, K. Al Saleh2, A. Bounedjar3, H. Abdel-Razeq4, H. Errihani5, A. Saadeddin6, M. Al Foheidi7, M. Ghosn8, H. El Zawahry9, A. Kandil10, N. Abdel-Aziz2, F. Dabouz11, S. Kullab2

Author affiliations

  • 1 Oncology Center, Medical Oncology, King Saud University Medical City (KSUMC), 11693 - Riyadh/SA
  • 2 Oncology Center, Medical Oncology, King Saud University Medical City (KSUMC), 7805 - Riyadh/SA
  • 3 Oncologie Médicale, Centre Hospitalo Universitaire de Blida, 09000 - Blida/DZ
  • 4 Hematology And Medical Oncology, King Hussein Cancer Center, 1269 - Amman/JO
  • 5 Oncologie Médicale, Institut National d'Oncologie université Mohammed V, 0000 - Rabat/MA
  • 6 Medical Oncology, National Guard Health Affairs (NGHA) - King AbdulAziz Medical City, 22490 - Riyadh/SA
  • 7 Medical Oncology, National Guard Health Affairs (NGHA) - King AbdulAziz Medical City, 21423 - Jeddah/SA
  • 8 Hematology - Oncology Department, Hôtel-Dieu de France, Université Saint-Joseph, 166830 - Beirut/LB
  • 9 Medical Oncology, National Cancer Institute (NCI)/ Cairo, 11796 - cairo/EG
  • 10 Department Of Clinical Oncology And Nuclear Medicine, Clinical research Center- Faculty of Medicine- Alexandria University, 21131 - Alexandria/EG
  • 11 Clinical research/ Data Management, International Cancer Research Group (ICRG), Sharjah/AE
More

Resources

Abstract 2010

Background

Neo-adjuvant (NA) chemotherapy (CT) +/- anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC. However, pathologic complete response (pCR) rates with CT in hormonal receptor+/Her2 negative BC are usually low: 7% (Luminal A) to 16% (Luminal B). Alternatively, NA endocrine therapy (ET) has not been established as a standard treatment because of low pCRs (i.e. 5% using 8 months of ET).

Trial design

This is a multicenter phase III, 3rd generation neo-adjuvant trial performed in 34 centers and 8 countries of Middle-East and Maghreb with the objective to investigate the potential role of the addition of a CDK 4/6 inhibitor (Palbociclib) to ET (Fulvestrant+/- Goseriline) compared to ET alone as neo-adjuvant therapy of HR+/ Her2- operable BC sensitive to ET. The question Is whether or not ET plus CDK 4/6 inhibitor would yield high enough pCR rates to establish this strategy as a reasonable therapeutic option in this group of patients (pts) with luminal HER2- BC. A total of 400 pts with stage II and IIIA are planned to be recruited in this trial. Oncotype DX will be performed upfront in order to eliminate CT candidates. All pre/peri and post-menopausal pts with a recurrence score < 31 will be treated with 4 months of Fulvestrant (500 mg Day (d.) 1, 14, 28 then q. 28 d. (+/- Goseriline 3.6 mg q.28 d.). Patients with responding/stable disease will then be randomized in double blind fashion to Fulvestrant (+/- Goseriline) either with Palbociclib 125mg po daily 3 weeks/4 or placebo. Four additional cycles will be delivered before surgery. The study primary endpoint is pCR while clinical/radiological response, rate of conservative surgery, safety, disease-free and overall survival are secondary endpoints. Exploratory endpoints encompass biomarker serial analysis of liquid biopsies with Quantum Optic and DNA methylation technologies. The SAFIA trial aims to identify a new neo-adjuvant standard with ET plus CDK 4/6 inhibitor in luminal - Her2 negative operable BC.

Clinical trial identification

SAFIA Study (ICRG 1201); NCT03447132.

Legal entity responsible for the study

International Cancer Research Group (ICRG).

Funding

AstraZeneca, Pfizer and Genomic Health.

Editorial Acknowledgement

not applicable

Disclosure

J-M. Nabholtz, F. Dabouz, S. Kullab: Research grants: AstraZeneca, Pfizer, Genomic Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.